2 months Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -3.03% and 24.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X